Logo for Genovis

Genovis Investor Relations Material

Latest events

Logo for Genovis

Q4 2023

15 Feb, 2024
Logo for Genovis

Q3 2023

15 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Segment Data
Access more data
Net sales by
Product category
Enzyme
Antibodies
Expenses by
Financials
Genovis AB designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company primarily provides site-specific polymerases, glycanases, antibodies, glycoengineered proteins, and other biopharmaceutical tools. It offers site-specific ADAMTS5 inhibitor; recombinant elastase with or without carbonyl-sulfonate glycosylation; recombinant neutrophil collagenase; recombinant rhinovirus 2C protease with 0 to 7 N-linked glycans; AA47G1; Nedd4 binding protein 2/Nedd4L RFP fusion protein; and monomeric red fluorescent protein variants. The company also provides antibodies, including renin activity assays; renin activity assay reagents; chymase activity assays; chymase activity assay reagents; as well as plasma renin activity tests. In addition, it offers GlycoSMART panels for deglycosylating individual glycoproteins for analysts at pharmaceutical and biotechnology companies engaged in glycoprotein production and analysis. The company sells its products through distributors in Sweden and internationally.